Nurix Therapeutics shares are trading higher after Morgan Stanley maintained an Equal-Weight rating on the stock and raised its price target from $9 to $10.
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics shares increased in value following Morgan Stanley's decision to maintain an Equal-Weight rating while raising the price target from $9 to $10.
February 26, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics' stock price is likely to experience a positive short-term impact due to Morgan Stanley's updated price target and maintained Equal-Weight rating.
Analyst ratings and price target adjustments are significant indicators for investors, influencing stock prices. Morgan Stanley's decision to raise the price target for Nurix Therapeutics while maintaining an Equal-Weight rating suggests a positive outlook on the stock, likely leading to increased investor confidence and a short-term price rise.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90